Combined Blockade of MEK and CDK4/6 Pathways Induces Senescence to Improve Survival in Pancreatic Ductal Adenocarcinoma

Activating KRAS mutations, a defining feature of pancreatic ductal adenocarcinoma (PDAC), promote tumor growth in part through the activation of cyclin-dependent kinases (CDKs) that induce cell cycle progression. p16(INK4a) (p16), encoded by the gene CDKN2A, is a potent inhibitor of CDK4/6 and serve...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Mol Cancer Ther
Päätekijät: Willobee, Brent A., Gaidarski, Alexander A., Dosch, Austin R., Castellanos, Jason A., Dai, Xizi, Mehra, Siddharth, Messaggio, Fanuel, Srinivasan, Supriya, VanSaun, Michael N., Nagathihalli, Nagaraj S., Merchant, Nipun B.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2021
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC8260447/
https://ncbi.nlm.nih.gov/pubmed/34001634
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-19-1043
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia